Precision BioSciences, Inc. Common Stock
DTIL US74019P1084
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-16% | -85% | -69% | -66% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Frankel Stanley |
4.97 USD |
2,700 Bought |
13,419 USD |
26/09/2025 | 26/09/2025 |
Brown Melinda |
4.89 USD |
1,400 Bought |
6,846 USD |
22/09/2025 | 22/09/2025 |
Kelly John Alexander CFO |
4.26 USD |
14,827 Sold |
63,163 USD |
03/07/2025 | 03/07/2025 |
Brown Melinda |
4.14 USD |
1,682 Bought |
6,963 USD |
25/06/2025 | 25/06/2025 |
Buehler Kevin |
4.16 USD |
5,076 Bought |
21,116 USD |
25/06/2025 | 25/06/2025 |
Buehler Kevin |
4.67 USD |
4,523 Bought |
21,122 USD |
26/03/2025 | 26/03/2025 |
Brown Melinda |
4.75 USD |
1,839 Bought |
8,735 USD |
26/03/2025 | 26/03/2025 |
Germano Geno J |
5.30 USD |
3,250 Bought |
17,225 USD |
25/03/2025 | 25/03/2025 |
Amoroso Michael CEO |
5.56 USD |
964 Sold |
5,360 USD |
21/03/2025 | 24/03/2025 |
Amoroso Michael CEO |
5.56 USD |
964 Sold |
5,360 USD |
21/03/2025 | 24/03/2025 |